Samsung Bioepis Wins U.S. Injunction Case Over Stelara Biosimilar
Samsung Bioepis has cleared a key legal hurdle in the U.S. market for its autoimmune disease biosimilar Pyzchiva,…
Pyzchiva
2 개의 기사가 있습니다.
Samsung Bioepis’ Autoimmune Disease Treatment ‘PYZCHIVA’ Approved in the U.S.
Samsung Bioepis has announced that its biosimilar to Stelara, named ‘Pyzchiva’ (project name SB17, active ingredient ustekinumab), has…